Pfizer Current and Emerging Therapies: The future of Recurrent or Metastatic (r/m) Cervical Cancer

Organization
Pfizer
Type
Industry
Application Due Date
09-01-2026
Brief Description

This competitive program seeks to provide educational grants to support continuing education projects focused on the evolving treatment landscape and disease management for patients with recurrent or metastatic (r/m) cervical cancer.